Litcius/Paper detail

Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their <i>In Vivo</i> Adjuvant Activity

Samo Guzelj, Sanja Nabergoj, Martina Gobec, Stane Pajk, Veronika Klančič, Bram Slütter, Ruža Frkanec, Adela Štimac, Primož Šket, Janez Plavec, Irena Mlinarič‐Raščan, Žiga Jakopin

2021Journal of Medicinal Chemistry25 citationsDOIOpen Access PDF

Abstract

showed promising adjuvant activity in mice, surpassing that of muramyl dipeptide, while achieving a more balanced Th1/Th2 immune response, thus highlighting its potential as a vaccine adjuvant.

Topics & Concepts

In vivoMuramyl dipeptideAdjuvantChemistryPeripheral blood mononuclear cellIn vitroPharmacologyNOD2Immune systemBiochemistryImmunologyReceptorBiologyInnate immune systemBiotechnologyImmune Response and InflammationAntimicrobial Peptides and ActivitiesPeptidase Inhibition and Analysis
Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their <i>In Vivo</i> Adjuvant Activity | Litcius